Related Experiment Videos

Antitumor effects of energy restriction-mimetic agents: thiazolidinediones

Hany A Omar1, Samir A Salama, El-Shaimaa A Arafa

  • 1Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.

Biological Chemistry
|April 25, 2013
PubMed

Insights

Thiazolidinediones (TZDs) show promise in cancer therapy by targeting tumor metabolism through pathways independent of peroxisome proliferator-activated receptor gamma (PPARγ). These agents offer potential for developing novel cancer treatments by influencing glucose metabolism and energy pathways.

Area of Science:

  • Oncology
  • Metabolic pathways
  • Pharmacology

Background:

  • Cancer cells exhibit distinct metabolic strategies, like increased glycolysis, for growth advantages.
  • Thiazolidinediones (TZDs) are known peroxisome proliferator-activated receptor gamma (PPARγ) ligands used as hypoglycemic agents.
  • Emerging evidence indicates TZDs possess anticancer properties via PPARγ-independent mechanisms.

Purpose of the Study:

  • To review recent advances in exploiting PPARγ-independent anticancer effects of TZDs.
  • To highlight novel agents targeting tumor metabolism based on TZD mechanisms.
  • To discuss the translational potential of these agents in cancer therapy.

Main Methods:

  • Review of current literature on TZD pharmacology and cancer metabolism.
  • Analysis of studies investigating PPARγ-independent mechanisms of TZDs.
  • Identification of therapeutic targets such as glucose transporters and AMPK.

Main Results:

  • TZDs can suppress cancer cell proliferation through apoptosis and autophagy modulation.
  • PPARγ-independent pathways are crucial for the anticancer effects of TZDs.
  • Targeting tumor metabolism with TZD-inspired agents shows translational potential.

Conclusions:

  • PPARγ-independent mechanisms of TZDs offer a novel therapeutic strategy for cancer.
  • Development of agents targeting glucose transporters and AMPK holds promise for cancer treatment.
  • TZDs and related compounds represent a valuable avenue for anticancer drug discovery.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...